Spots Global Cancer Trial Database for Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab

Official Title: Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab

Study ID: NCT01312493

Conditions

Head and Neck Cancer

Interventions

Panitumumab

Intensity Modulated Radiation Therapy

Study Description

Brief Summary: This is a non-randomized phase II study of targeted radiotherapy (RT) administered concurrently with panitumumab in patients with locally advanced squamous carcinoma of the head and neck.

Detailed Description: This is a non-randomized phase II trial of targeted radiotherapy (RT) administered concurrently with panitumumab in patients with locally advanced squamous cell carcinoma of the head and neck. This protocol addresses patients with medical comorbidities that make them poor candidates for concurrent chemotherapy. Radiotherapy treatment will be directed at disease visible on diagnostic imaging modalities and the ipsilateral hemi-neck, sparing elective regions in the contralateral N0 hemi-neck with less than 20% chance of microscopic involvement. We explore the following hypothesis: Can acceptable locoregional disease control be obtained with less treatment-related morbidity by focusing RT on regions of gross disease, sparing regions with a low risk of harboring subclinical disease from elective RT?